Global Regulatory Strategy

For Early Certainty,
Worldwide

Unsure if you can keep up with evolving standards, diversity requirements, and complex modalities? Our global regulatory strategy services move at the speed of science, giving you early agency engagement and strong regional alignment to reduce risk and increase confidence.

The First Step on Your Path to Market

Clinical development success starts with a well-planned global regulatory strategy that identifies potential challenges and supports informed decisions. Which is exactly what Caidya offers.

Focusing on early alignment, our regulatory experts:

Smooth Your Global Pathway

We harmonize global endpoints, comparators, and statistics expectations, so you can hit the ground running — without reworks or amendments.

Prove Your Product’s Worth

We build robust evidence packages aligned to diverse agency benefit-risk expectations, anticipating differences in clinical outcomes versus risk minimization to guide smarter program decisions and reduce regulatory risk.

Support Your Advanced Therapy

The cutting-edge is where we thrive. Whether you’re working on cell, gene, or other advanced therapies, we engage with agencies early and create tailored strategies for modality-specific risks to reduce uncertainty.

Incorporate Your CMC Strategy

We consider critical chemistry, manufacturing, and controls (CMC) strategy on day one, so you don’t have to worry about delays or gaps.

Make Smarter Program Decisions

Do you know every nuance between the FDA, EMA, NMPA and other regulatory bodies? We do.

Across regions and modalities, we align your target product profile and evidence to global expectations, build multi-region-ready packages, embed estimands and diversity planning early, and link cell therapy strategy to CMC readiness, keeping you on time, in budget, and set up for success.

With our global regulatory strategy services, you’ll:

Meet Evolving Expectations

We define estimands and plan for intercurrent events from day one, lining up your goals with ever-changing clinical trial regulatory requirements.

Incorporate Diversity

Diversity requirements are never an afterthought here. We align recruitment strategies and operational execution to create a compliant Diversity Action Plan that improves representation and avoids delays down the line

Navigate Complex Global Pathways

We make sure your endpoints, comparators, and statistical approaches match up with your ideal regulatory pathway, reducing protocol churn, avoiding extra studies, and keeping your timeline on track.

Advance Your Cell Therapy

We maintain compliance with global and local health authority policies and regulations, delivering CMC-informed filings so you don’t have to worry about regulatory compliance.

At Caidya, we help sponsors navigate complex global regulatory pathways with strategic insight and strong agency relationships so therapies can progress from clinic to approval.

Blaine VanLeuven - Executive Director Regulatory & Strategic Development

Our Global Regulatory Strategy Services

Along with our clinical trial Regulatory Services, we help you find the best path for your product with:

  • Global alignment
  • Evidence/benefit–risk planning
  • Diversity planning
  • Complex modality planning
  • Cell therapy CMC considerations and strategy integration
  • Health authority responses
  • Bridging study evaluation report
  • FDA orphan drug support

Confidently Meet Regulatory Requirements

Why struggle through uncertainty? Let us help you:

  • Choose the right pathway for regulatory approval
  • Align to global expectations spanning FDA, EMA, MHRA, PMDA, and NMPA
  • Manage complex modalities for gene, cell, and advanced therapies that often face ambiguous regulatory pathways
  • Set your diversity goals by aligning your recruitment strategies with regulatory requirements

Related Insights

Clinical Regulatory Services Article Regulatory factors in rare disease studies Blog Regulatory Challenges for Chinese Biotech Expanding Trials to Europe Regulatory Update Global Regulatory Updates on Clinical Trials (May 2026) Regulatory Update Global Regulatory Updates on Clinical Trials (April 2026) Regulatory Update Global Regulatory Updates on Clinical Trials (March 2026) Regulatory Update Global Regulatory Updates on Clinical Trials (February 2026) Regulatory Update Global Regulatory Updates on Clinical Trials (January 2026) Regulatory Update Global Regulatory Updates on Clinical Trials (December 2025) Regulatory Update Global Regulatory Updates on Clinical Trials (November 2025)

Frequently Asked Questions About
Global Regulatory Strategy

How do you align global regulatory expectations early to avoid protocol changes later?

Early alignment comes from engaging key agencies, mapping regional requirements for endpoints, comparators, and statistics, and building a unified strategy that anticipates divergence before protocols are finalized.

How do you plan an evidence package when benefit–risk expectations differ across regions?

A flexible evidence strategy is developed that addresses varying regional benefit–risk frameworks by combining core global data with region-specific analyses and endpoints where needed.

How do you approach regulatory strategy for complex modalities where pathways are evolving?

We use early scientific advice, adaptive planning, and iterative regulatory engagement to navigate uncertainty and tailor development strategies to evolving modality-specific expectations.

How do estimands and intercurrent events affect regulatory strategy and statistical planning?

They define how treatment effects are measured over time, requiring clear pre-specification of handling strategies to ensure analyses are interpretable and aligned with regulatory expectations.

How do diversity expectations influence regulatory strategy and trial planning?

Diversity requirements shape enrollment strategies, site selection, and operational planning to ensure representative populations and meet regulatory expectations for inclusivity and data relevance.

When should sponsors engage with agencies during Phases I–III to reduce downstream risk?

Engagement should begin early in Phase I and continue through development milestones to align on key decisions and reduce the risk of late-stage regulatory surprises.

What CMC topics most commonly drive regulatory risk in cell therapy development?

Key risks include manufacturing controls, product characterization, sterility assurance, potency testing, delivery device suitability, and consistency of production processes.

How do manufacturing controls and aseptic processing considerations affect filing readiness?

Manufacturers need to adopt strict aseptic manufacturing procedures to ensure product quality and reproducibility, forming the foundation of regulatory confidence in safety, consistency, and compliance for cell therapy submissions.

What are common expectations around container closure systems and delivery devices for cell therapies?

Manufacturers need to demonstrate the compatibility of the cell therapy products with the container closure system. Regulators expect validated systems that ensure product integrity, sterility, and compatibility throughout storage, transport, and administration.

What stability considerations are critical for cell therapy regulatory packages?

Manufacturers should demonstrate that the stability of a formulated cell therapy product in its final container closure system remains stable and meets specifications throughout the intended shelf-life. Stability programs must demonstrate product viability, potency, and safety over defined storage and handling conditions to support shelf-life claims and reliable clinical use.